Neal D. Shore, MD, FACS

Articles by Neal D. Shore, MD, FACS

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Chandler Park, MD, and Neal D. Shore, MD, FACS, hand community practices a concrete playbook for offering immunotherapy with BCG.

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Neal D. Shore, MD, FACS, and Chandler Park, MD, further discuss POTOMAC data, including a 37% lower rate of cystectomy, subgroup HRs as low as 0.48, and 5-year OS data with no detriment.

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Chandler Park, MD, and Neal D. Shore, MD, FACS, trace immune-related adverse events from melanoma's early days to today's playbook for community urology.

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Neal D. Shore, MD, FACS, walks through exactly how POTOMAC's design showed durvalumab (Imfinzi) plus BCG improved disease-free survival in NMIBC.

High-Risk BCG-Naive NMIBC: Where Treatment Falls Short Today

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 18th 2026

Neal D. Shore, MD, FACS, and Chandler Park, MD, share how the POTOMAC data, and a newly FDA-approved combination, are opening up shared decision-making with patients.